FDA approves Astellas drug for preventing kidney rejection

Drug approved for use with CellCept, corticosteroids, Simulect

NORTHBROOK, Ill. — The Food and Drug Administration has approved a drug made by Japanese drug maker Astellas for preventing the body from rejecting transplanted organs, the company said.

Astellas announced through a U.S. subsidiary that the FDA had approved Astagraf XLTM (tacrolimus) extended-release capsules for preventing rejection of transplanted kidneys, for use with Genentech's CellCept (mycophenolate mofetil) and corticosteroids, with or without Simulect (basiliximab), a biotech drug made by Swiss drug maker Novartis.

"Each transplant recipient is different and requires a personalized treatment approach," Astellas Pharma chief medical officer Sef Kurstjens said. "Astellas is pleased to continue our more than 20-year commitment to the field of transplant immunology."

Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

Login or Register to post a comment.